This book includes a plain text version that is designed for high accessibility. To use this version please follow this link.
10-09 :: September 2010


nanotimes


Companies Facts


Nano-Cancer® therapy uses iron oxide nanoparticles,


which are injected into the tumor and, due to their special coating, aggregate and remain in place. The patient is then placed into a magnetic field applica- tor. Through the application of an alternating magne- tic field, the nanoparticles begin to oscillate, produce warmth, and damage or kill the tumor tissue.


The study data, published on September 20, 2010 in the Journal of Neuro-Oncology, is available online. http://www.magforce.com


Klaus Maier-Hauff, Frank Ulrich, Dirk Nestler, Hendrik Niehoff, Peter Wust, Burghard Thiesen, Helmut Orawa, Volker Budach and Andreas Jordan: Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide na- noparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme, In: Journal of Neuro-Oncology, Online First, DOI:10.1007/s11060- 010-0389-0:


http://dx.doi.org/10.1007/s11060-010-0389-0 M


asdar PV, a manufacturer of large-surface thin-film solar modules, has improved the


efficiency of its solar modules to 7.4%, based on the semiconductor amorphous silicon (a-Si). The incre- ase of over 15% was made possible over the past six months by in-house process know-how, as a result of which additional and optimised production steps and improved quality checks have been introduced. Masdar PV is thus reinforcing its position as one of the most efficient providers of a-Si thin-film modules. http://www.masdarpv.com


M


iaSolé, the leading manufacturer of copper indium gallium selenide (CIGS) thin-film


photovoltaic solar panels, announced that the U.S.


Department of Energy‘s National Renewable Ener- gy Laboratory (NREL) independently confirmed the 14.3% efficiency of its large area production modules (1 square meter in size). 14.3% module efficiency is the highest independently confirmed efficiency for any commercial scale CIGS module technology.


“We are pleased that we continue to make progress in the execution of our technology, cost reduction and manufacturing roadmaps,” said Dr. Joseph Laia, CEO of MiaSolé. http://www.MiaSole.com


N


anoco Group plc (AIM: NANO), a world leader in the development and manufacture of quan-


tum dots and other nanomaterials, has achieved a key milestone in its agreement with a major Japanese electronics company for the design and development of quantum dots for use in the LED backlighting of LCD TVs, triggering a US$600,000 milestone pay- ment.


The 18-month development agreement, which was announced in September 2009, has a final milestone remaining and is on schedule for completion in early 2011. On completion, it is expected that a supply and licence agreement will be negotiated with the partner.


http://www.nanocotechnologies.com


N N


anoFocus (N2F.FSE), Germany, published its Annual Report for 2009. http://www.nanofocus.de/publikationen.html?&L=0


anogate (ISIN DE000A0JKHC9 improves market position in Austria after having suc-


cessfully entered the market last year, the company


35


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81